Bruker Corporation (BRKR) - Net Assets
Based on the latest financial reports, Bruker Corporation (BRKR) has net assets worth $2.51 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.24 Billion) and total liabilities ($3.73 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BRKR financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.51 Billion |
| % of Total Assets | 40.22% |
| Annual Growth Rate | 22.56% |
| 5-Year Change | 131.41% |
| 10-Year Change | 262.18% |
| Growth Volatility | 212.4 |
Bruker Corporation - Net Assets Trend (1998–2025)
This chart illustrates how Bruker Corporation's net assets have evolved over time, based on quarterly financial data. Also explore Bruker Corporation assets under control for the complete picture of this company's asset base.
Annual Net Assets for Bruker Corporation (1998–2025)
The table below shows the annual net assets of Bruker Corporation from 1998 to 2025. For live valuation and market cap data, see BRKR market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.51 Billion | +38.29% |
| 2024-12-31 | $1.82 Billion | +28.44% |
| 2023-12-31 | $1.41 Billion | +24.87% |
| 2022-12-31 | $1.13 Billion | +4.33% |
| 2021-12-31 | $1.08 Billion | +11.34% |
| 2020-12-31 | $974.30 Million | +3.85% |
| 2019-12-31 | $938.20 Million | +3.66% |
| 2018-12-31 | $905.10 Million | +23.39% |
| 2017-12-31 | $733.50 Million | +5.83% |
| 2016-12-31 | $693.10 Million | -5.43% |
| 2015-12-31 | $732.90 Million | -5.03% |
| 2014-12-31 | $771.70 Million | -9.23% |
| 2013-12-31 | $850.20 Million | +19.81% |
| 2012-12-31 | $709.60 Million | +13.55% |
| 2011-12-31 | $624.90 Million | +18.49% |
| 2010-12-31 | $527.40 Million | +25.93% |
| 2009-12-31 | $418.80 Million | +33.93% |
| 2008-12-31 | $312.70 Million | +20.64% |
| 2007-12-31 | $259.20 Million | +35.21% |
| 2006-12-31 | $191.71 Million | -7.85% |
| 2005-12-31 | $208.03 Million | -4.34% |
| 2004-12-31 | $217.47 Million | +7.37% |
| 2003-12-31 | $202.55 Million | +60.27% |
| 2002-12-31 | $126.38 Million | -0.92% |
| 2001-12-31 | $127.55 Million | +2.72% |
| 2000-12-31 | $124.17 Million | +1134.60% |
| 1999-12-31 | $10.06 Million | -2.73% |
| 1998-12-31 | $10.34 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bruker Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 236180000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.36 Billion | 96.14% |
| Common Stock | $1.80 Million | 0.07% |
| Other Comprehensive Income | $-79.50 Million | -3.24% |
| Other Components | $172.40 Million | 7.02% |
| Total Equity | $2.46 Billion | 100.00% |
Bruker Corporation Competitors by Market Cap
The table below lists competitors of Bruker Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enel Chile SA ADR
NYSE:ENIC
|
$5.60 Billion |
|
BRF S.A
SA:BRFS3
|
$5.61 Billion |
|
Strathcona Resources Ltd.
TO:SCR
|
$5.61 Billion |
|
Flagstar Financial, Inc.
NYSE:FLG
|
$5.62 Billion |
|
Ningbo Zhenyu Technology Co. Ltd.
SHE:300953
|
$5.60 Billion |
|
LS Electric
KO:010120
|
$5.60 Billion |
|
CG Oncology, Inc. Common stock
NASDAQ:CGON
|
$5.60 Billion |
|
Hindustan Copper Limited
NSE:HINDCOPPER
|
$5.59 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bruker Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,781,200,000 to 2,456,500,000, a change of 675,300,000 (37.9%).
- Net loss of 8,600,000 reduced equity.
- Dividend payments of 22,800,000 reduced retained earnings.
- Share repurchases of 10,000,000 reduced equity.
- New share issuances of 677,600,000 increased equity.
- Other comprehensive income increased equity by 24,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.60 Million | -0.35% |
| Dividends Paid | $22.80 Million | -0.93% |
| Share Repurchases | $10.00 Million | -0.41% |
| Share Issuances | $677.60 Million | +27.58% |
| Other Comprehensive Income | $24.00 Million | +0.98% |
| Other Changes | $15.10 Million | +0.61% |
| Total Change | $- | 37.91% |
Book Value vs Market Value Analysis
This analysis compares Bruker Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.27x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 161.89x to 2.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $0.23 | $36.79 | x |
| 1999-12-31 | $0.22 | $36.79 | x |
| 2000-12-31 | $2.21 | $36.79 | x |
| 2001-12-31 | $2.36 | $36.79 | x |
| 2002-12-31 | $2.40 | $36.79 | x |
| 2003-12-31 | $1.96 | $36.79 | x |
| 2004-12-31 | $2.25 | $36.79 | x |
| 2005-12-31 | $2.05 | $36.79 | x |
| 2006-12-31 | $1.87 | $36.79 | x |
| 2007-12-31 | $1.57 | $36.79 | x |
| 2008-12-31 | $1.88 | $36.79 | x |
| 2009-12-31 | $2.54 | $36.79 | x |
| 2010-12-31 | $3.18 | $36.79 | x |
| 2011-12-31 | $3.74 | $36.79 | x |
| 2012-12-31 | $4.22 | $36.79 | x |
| 2013-12-31 | $5.05 | $36.79 | x |
| 2014-12-31 | $4.55 | $36.79 | x |
| 2015-12-31 | $4.33 | $36.79 | x |
| 2016-12-31 | $4.27 | $36.79 | x |
| 2017-12-31 | $4.61 | $36.79 | x |
| 2018-12-31 | $5.76 | $36.79 | x |
| 2019-12-31 | $5.79 | $36.79 | x |
| 2020-12-31 | $6.22 | $36.79 | x |
| 2021-12-31 | $7.00 | $36.79 | x |
| 2022-12-31 | $7.46 | $36.79 | x |
| 2023-12-31 | $9.36 | $36.79 | x |
| 2024-12-31 | $11.91 | $36.79 | x |
| 2025-12-31 | $16.18 | $36.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bruker Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.25%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 2.54x
- Recent ROE (-0.35%) is below the historical average (11.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -8.59% | -2.10% | 0.66x | 6.17x | $-1.92 Million |
| 1999 | 12.42% | 1.93% | 0.96x | 6.69x | $243.75K |
| 2000 | 1.81% | 2.94% | 0.42x | 1.49x | $-10.17 Million |
| 2001 | 2.85% | 3.92% | 0.49x | 1.48x | $-9.12 Million |
| 2002 | -4.91% | -5.33% | 0.57x | 1.61x | $-18.84 Million |
| 2003 | -8.67% | -6.73% | 0.74x | 1.73x | $-37.80 Million |
| 2004 | -3.60% | -2.75% | 0.77x | 1.71x | $-29.56 Million |
| 2005 | 1.75% | 1.23% | 0.82x | 1.74x | $-17.13 Million |
| 2006 | 9.65% | 4.24% | 1.01x | 2.26x | $-665.60K |
| 2007 | 12.19% | 5.76% | 0.99x | 2.14x | $5.66 Million |
| 2008 | 20.81% | 5.86% | 0.99x | 3.58x | $33.71 Million |
| 2009 | 19.39% | 7.29% | 0.95x | 2.80x | $39.32 Million |
| 2010 | 18.09% | 7.31% | 0.84x | 2.94x | $42.66 Million |
| 2011 | 14.77% | 5.59% | 0.97x | 2.74x | $29.81 Million |
| 2012 | 10.97% | 4.33% | 0.96x | 2.63x | $6.84 Million |
| 2013 | 9.42% | 4.35% | 0.93x | 2.34x | $-4.92 Million |
| 2014 | 7.35% | 3.13% | 0.97x | 2.42x | $-20.47 Million |
| 2015 | 13.86% | 6.26% | 0.94x | 2.36x | $28.31 Million |
| 2016 | 22.16% | 9.53% | 0.89x | 2.62x | $84.29 Million |
| 2017 | 10.72% | 4.45% | 0.91x | 2.66x | $5.25 Million |
| 2018 | 19.85% | 9.48% | 0.89x | 2.35x | $89.19 Million |
| 2019 | 21.75% | 9.51% | 0.75x | 3.06x | $106.52 Million |
| 2020 | 16.42% | 7.94% | 0.65x | 3.17x | $61.68 Million |
| 2021 | 25.89% | 11.46% | 0.66x | 3.41x | $170.05 Million |
| 2022 | 26.63% | 11.72% | 0.70x | 3.24x | $185.22 Million |
| 2023 | 31.02% | 14.41% | 0.70x | 3.09x | $289.48 Million |
| 2024 | 6.35% | 3.36% | 0.58x | 3.26x | $-65.02 Million |
| 2025 | -0.35% | -0.25% | 0.55x | 2.54x | $-254.25 Million |
Industry Comparison
This section compares Bruker Corporation's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,555,245,291
- Average return on equity (ROE) among peers: -57.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bruker Corporation (BRKR) | $2.51 Billion | -8.59% | 1.49x | $5.60 Billion |
| Abbott Laboratories (ABT) | $24.08 Billion | 18.37% | 0.83x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $1.47 Billion | -46.29% | 2.07x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $15.99 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.10 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $30.20 Million | 15.56% | 0.78x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $125.55 Million |
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, ser… Read more